ENO2 and lung cancer: Additionally, Li et al. observed that serum tumor marker sensitivity was 28.46% for CEA, 19.51% for CA 125, 3.25% for NSE, 50.41% for CYFRA 21‐1, 26.02% for SCC and 11.38% for pro‐GRP in lung cancer patients (188).